A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer

Breast cancer (BC) has a high mortality rate and metastatic BC is almost incurable despite hormonal therapy and chemotherapy. The second and third lines of chemotherapies usually yield transient responses and the median survival is generally as low as 18-24 months. Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) have been extensively investigated in this setting. The presence of immune mediated anti-tumor effects referred to as graft-versus-tumor (GvT) effects after allogeneic HSCT among patients with solid tumors have been clearly defined. The advantages of allogeneic HSCT over autologous HSCT for metastatic BC are i) cancer-free graft and ii) immune-mediated GvT effects mediated by human leukocyte antigen compatible donor T-cells. In conclusion, a GvT effect does exist against metastatic BC and play a key role in tumor response. This review aims to describe the background, rationale, and clinical results of allogeneic HSCT as a potential alternative treatment in metastatic BC.

[1]  P. Pedrazzoli,et al.  Is adoptive T-cell therapy for solid tumors coming of age? , 2012, Bone Marrow Transplantation.

[2]  D. Berry,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Berry,et al.  High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Dini,et al.  28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures , 2008, Bone Marrow Transplantation.

[5]  P. Pedrazzoli,et al.  Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors , 2008, Nature Clinical Practice Oncology.

[6]  D. Blaise,et al.  Allogeneic hematopoietic cell transplantation for metastatic breast cancer , 2008, Bone Marrow Transplantation.

[7]  F. Grosso,et al.  Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. , 2007, Haematologica.

[8]  J. Ledermann,et al.  High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Mark Ende,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.

[10]  P. Pedrazzoli,et al.  Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  G. Dini,et al.  Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours , 2005, British Journal of Cancer.

[12]  A. Ballestrero,et al.  Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer , 2005, The Lancet.

[13]  M. Aglietta,et al.  Allogeneic hemopoietic stem cell transplantation in solid tumors. , 2005, Transplantation proceedings.

[14]  S. Steinberg,et al.  Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Dini,et al.  Hematopoetic stem cell transplantation for solid tumors in Europe. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  D. Blaise,et al.  Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. , 2004, Blood.

[17]  N. Kröger,et al.  Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients , 2003, Bone Marrow Transplantation.

[18]  G. Hortobagyi,et al.  Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. , 2003, Blood.

[19]  M. Marangolo,et al.  Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999 , 2003, Bone Marrow Transplantation.

[20]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Piccart,et al.  Chemotherapy for metastatic breast cancer-report of a European expert panel. , 2002, The Lancet. Oncology.

[22]  C. Voena,et al.  Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. , 2002, Blood.

[23]  J Wagner,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[24]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[25]  S. Slavin,et al.  Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[26]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[27]  D. Wickerham,et al.  Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  O. Ilhan,et al.  Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.

[29]  W. Nichols,et al.  High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer , 1998, Bone Marrow Transplantation.

[30]  A. Diab,et al.  Allogeneic cell therapy for a murine mammary carcinoma. , 1998, Cancer research.

[31]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Hortobagyi,et al.  Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[34]  D. Wickerham,et al.  Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Storb,et al.  Syngeneic marrow transplantation in patients with multiple myeloma. , 1996, Bone marrow transplantation.

[36]  C. Marth,et al.  Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. , 1996, Blood.

[37]  R. Storb,et al.  Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia. , 1996, Bone marrow transplantation.

[38]  R. Storb,et al.  High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. , 1996, Bone marrow transplantation.

[39]  R. Storb,et al.  Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. , 1996, Bone marrow transplantation.

[40]  R. Storb,et al.  Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. , 1996, Bone marrow transplantation.

[41]  S. Giralt,et al.  Donor lymphocyte infusions , 1996, Current opinion in oncology.

[42]  R. Storb,et al.  Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. , 1994, Bone marrow transplantation.

[43]  B. Asselain,et al.  Age as prognostic factor in premenopausal breast carcinoma , 1993, The Lancet.

[44]  J. Torhorst,et al.  Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  K. Antman,et al.  New developments in clinical oncology: the interdependence of bench and bedside. , 1991, Cancer research.

[46]  L. Sleeper,et al.  Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Gelber,et al.  Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis , 1986, Cancer.

[48]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Slavin,et al.  Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. , 1984, Journal of immunology.

[50]  L. Arrighi,et al.  [Treatment of breast cancer]. , 1971, Prensa medica argentina.

[51]  J. Loutit,et al.  Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.

[52]  G. Bonadonna,et al.  Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer , 2005, Breast Cancer Research and Treatment.

[53]  W. Siegert,et al.  Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  H. Rockette,et al.  Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy , 2005, Breast Cancer Research and Treatment.

[55]  S. Panigrahi,et al.  Intraportal and systemic allogeneic cell therapy in a murine model of hepatic metastatic breast cancer. , 2002, Cytokines, cellular & molecular therapy.

[56]  A. Carella,et al.  Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer. , 2002, Cancer treatment and research.

[57]  D. Venzon,et al.  Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-betaI. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[58]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[59]  M. Levine,et al.  Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. , 1986, NCI monographs : a publication of the National Cancer Institute.